RNS Number : 0309A

AstraZeneca PLC

22 May 2023

   22 May 2023   07:05 BST 

Non-Executive Board Appointment

AstraZeneca PLC announced today that Anna Manz has been appointed as a Non-Executive Director and a member of the Audit Committee with effect from 1 September 2023.

Anna is currently an Executive Director and the Group Chief Financial Officer of London Stock Exchange Group plc.

Michel Demaré, Chair of AstraZeneca, said "We are delighted to welcome Anna to the AstraZeneca Board. She brings extensive cross-sector business skills and knowledge to the Board, having held international roles in North America and Asia Pacific and served as an executive and non-executive in large, listed companies. Anna's significant financial and strategic leadership experience, including in areas such as risk, treasury and accounting, will enable her to fully contribute to the work of our Audit Committee."

Biographical details - Anna Manz

Anna joined London Stock Exchange Group plc in November 2020 as Chief Financial Officer, ahead of the $27 billion acquisition of Refinitiv. From 2016 - 2020, she was an Executive Director and the Chief Financial Officer of Johnson Matthey Plc and led its Finance, Procurement and IT functions. Prior to joining Johnson Matthey, Anna spent 17 years at Diageo plc in a number of senior finance roles, including Chief Strategy Officer and as a member of the Executive Committee. She brings extensive expertise in accounting, corporate finance and mergers and acquisitions, as well as experience of business diversification and transformation.

Anna has been a Non-Executive Director of ITV plc since 2016 and has served on its Audit Committee and Remuneration Committee for most of that period. She will step down as a Non-Executive Director of ITV at the end of August this year.

Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Financial Conduct Authority's Listing Rules in respect of this appointment.


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .


For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 22, 2023 02:05 ET (06:05 GMT)

Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Set 2023 até Out 2023 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Out 2022 até Out 2023 Click aqui para mais gráficos Astrazeneca.